Literature DB >> 31614113

Thrown for a Loop: Awakening BORIS to Evade ALK Inhibition Therapy.

Esther R Berko1, Yael P Mossé2.   

Abstract

Mechanisms of acquired resistance to ALK inhibition therapy in neuroblastoma have not yet been elucidated. In a recent issue of Nature, Debruyne et al. demonstrate that resistant MYCN-amplified ALK-mutated neuroblastoma cells overexpress BORIS, resulting in wide-ranging changes in chromatin interaction and transcriptional reprogramming.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31614113      PMCID： PMC8132214          DOI： 10.1016/j.ccell.2019.09.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Authors:  Scott C Bresler; Andrew C Wood; Elizabeth A Haglund; Joshua Courtright; Lili T Belcastro; Jefferson S Plegaria; Kristina Cole; Yana Toporovskaya; Huaqing Zhao; Erica L Carpenter; James G Christensen; John M Maris; Mark A Lemmon; Yaël P Mossé
Journal:  Sci Transl Med       Date:  2011-11-09       Impact factor: 17.956

2.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

3.  Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Authors:  Thomas F Eleveld; Derek A Oldridge; Virginie Bernard; Jan Koster; Léo Colmet Daage; Sharon J Diskin; Linda Schild; Nadia Bessoltane Bentahar; Angela Bellini; Mathieu Chicard; Eve Lapouble; Valérie Combaret; Patricia Legoix-Né; Jean Michon; Trevor J Pugh; Lori S Hart; JulieAnn Rader; Edward F Attiyeh; Jun S Wei; Shile Zhang; Arlene Naranjo; Julie M Gastier-Foster; Michael D Hogarty; Shahab Asgharzadeh; Malcolm A Smith; Jaime M Guidry Auvil; Thomas B K Watkins; Danny A Zwijnenburg; Marli E Ebus; Peter van Sluis; Anne Hakkert; Esther van Wezel; C Ellen van der Schoot; Ellen M Westerhout; Johannes H Schulte; Godelieve A Tytgat; M Emmy M Dolman; Isabelle Janoueix-Lerosey; Daniela S Gerhard; Huib N Caron; Olivier Delattre; Javed Khan; Rogier Versteeg; Gudrun Schleiermacher; Jan J Molenaar; John M Maris
Journal:  Nat Genet       Date:  2015-06-29       Impact factor: 38.330

4.  Neuroblastoma is composed of two super-enhancer-associated differentiation states.

Authors:  Tim van Groningen; Jan Koster; Linda J Valentijn; Danny A Zwijnenburg; Nurdan Akogul; Nancy E Hasselt; Marloes Broekmans; Franciska Haneveld; Natalia E Nowakowska; Johannes Bras; Carel J M van Noesel; Aldo Jongejan; Antoine H van Kampen; Linda Koster; Frank Baas; Lianne van Dijk-Kerkhoven; Margriet Huizer-Smit; Maria C Lecca; Alvin Chan; Arjan Lakeman; Piet Molenaar; Richard Volckmann; Ellen M Westerhout; Mohamed Hamdi; Peter G van Sluis; Marli E Ebus; Jan J Molenaar; Godelieve A Tytgat; Bart A Westerman; Johan van Nes; Rogier Versteeg
Journal:  Nat Genet       Date:  2017-06-26       Impact factor: 38.330

5.  BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.

Authors:  David N Debruyne; Ruben Dries; Satyaki Sengupta; Davide Seruggia; Yang Gao; Bandana Sharma; Hao Huang; Lisa Moreau; Michael McLane; Daniel S Day; Eugenio Marco; Ting Chen; Nathanael S Gray; Kwok-Kin Wong; Stuart H Orkin; Guo-Cheng Yuan; Richard A Young; Rani E George
Journal:  Nature       Date:  2019-08-07       Impact factor: 49.962

6.  ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

Authors:  Scott C Bresler; Daniel A Weiser; Peter J Huwe; Jin H Park; Kateryna Krytska; Hannah Ryles; Marci Laudenslager; Eric F Rappaport; Andrew C Wood; Patrick W McGrady; Michael D Hogarty; Wendy B London; Ravi Radhakrishnan; Mark A Lemmon; Yaël P Mossé
Journal:  Cancer Cell       Date:  2014-11-10       Impact factor: 31.743

7.  The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

Authors:  Nicole R Infarinato; Jin H Park; Kateryna Krytska; Hannah T Ryles; Renata Sano; Katherine M Szigety; Yimei Li; Helen Y Zou; Nathan V Lee; Tod Smeal; Mark A Lemmon; Yael P Mossé
Journal:  Cancer Discov       Date:  2015-11-10       Impact factor: 39.397

8.  Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries.

Authors:  Valentina Boeva; Caroline Louis-Brennetot; Agathe Peltier; Simon Durand; Cécile Pierre-Eugène; Virginie Raynal; Heather C Etchevers; Sophie Thomas; Alban Lermine; Estelle Daudigeos-Dubus; Birgit Geoerger; Martin F Orth; Thomas G P Grünewald; Elise Diaz; Bertrand Ducos; Didier Surdez; Angel M Carcaboso; Irina Medvedeva; Thomas Deller; Valérie Combaret; Eve Lapouble; Gaelle Pierron; Sandrine Grossetête-Lalami; Sylvain Baulande; Gudrun Schleiermacher; Emmanuel Barillot; Hermann Rohrer; Olivier Delattre; Isabelle Janoueix-Lerosey
Journal:  Nat Genet       Date:  2017-07-24       Impact factor: 38.330

9.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.

Authors:  Sydney M Shaffer; Margaret C Dunagin; Stefan R Torborg; Eduardo A Torre; Benjamin Emert; Clemens Krepler; Marilda Beqiri; Katrin Sproesser; Patricia A Brafford; Min Xiao; Elliott Eggan; Ioannis N Anastopoulos; Cesar A Vargas-Garcia; Abhyudai Singh; Katherine L Nathanson; Meenhard Herlyn; Arjun Raj
Journal:  Nature       Date:  2017-06-07       Impact factor: 49.962

10.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

Authors:  Aaron N Hata; Matthew J Niederst; Hannah L Archibald; Maria Gomez-Caraballo; Faria M Siddiqui; Hillary E Mulvey; Yosef E Maruvka; Fei Ji; Hyo-eun C Bhang; Viveksagar Krishnamurthy Radhakrishna; Giulia Siravegna; Haichuan Hu; Sana Raoof; Elizabeth Lockerman; Anuj Kalsy; Dana Lee; Celina L Keating; David A Ruddy; Leah J Damon; Adam S Crystal; Carlotta Costa; Zofia Piotrowska; Alberto Bardelli; Anthony J Iafrate; Ruslan I Sadreyev; Frank Stegmeier; Gad Getz; Lecia V Sequist; Anthony C Faber; Jeffrey A Engelman
Journal:  Nat Med       Date:  2016-02-01       Impact factor: 53.440
  10 in total
  2 in total

Review 1.  Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.

Authors:  Yang Yang; Shuo Li; Yujiao Wang; Yi Zhao; Qiu Li
Journal:  Signal Transduct Target Ther       Date:  2022-09-17

Review 2.  Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Authors:  Lucy Hare; G A Amos Burke; Suzanne D Turner
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.